We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis
Read MoreHide Full Article
Biogen Inc. (BIIB - Free Report) announced that it has exercised the option to obtain worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306 from its partner Ionis Pharmaceuticals, Inc. (IONS - Free Report) . The investigational antisense oligonucleotide, BIIB115, is currently in pre-clinical development for treating spinal muscular atrophy (“SMA”).
Biogen paid $60 million to Ionis in the fourth quarter of 2021 as a part of the option exercised. The company may also make potential development, regulatory and commercial milestone payments as well as royalty payments on net sales upon potential approval. Biogen will advance the candidate to clinical studies and will now solely bear all costs and expenses related to the development, manufacturing and commercialization of BIIB115.
Shares of Biogen have decreased 2.4% in the past year compared with the industry’s decline of 22.8%.
Image Source: Zacks Investment Research
Shares of Ionis have plunged 44.2% in the past year compared with the industry’s decrease of 19.5%.
Image Source: Zacks Investment Research
Biogen has in-licensed Spinraza from Ionis, which is approved for treating SMA. Biogen is responsible for commercializing the drug globally. Ionis receives royalties from Biogen on Spinraza’s sales.
Biogen has expanded its collaboration with Ionis to identify new gene therapies for the treatment of SMA as well as a broad range of neurological diseases. Under these collaborations, the companies are currently developing eight medicines to treat neurodegenerative diseases like amyotrophic lateral sclerosis (“ALS”), Alzheimer’s disease and Parkinson’s disease.
Some candidates that Ionis is developing in partnership with Biogen are tofersen for SOD1-ALS (phase III), ION541 for ALS (phase II) and ION859 for Parkinson’s disease (phase II).
Spinraza has performed beyond expectations, witnessing strong patient uptake in the United States and internationally, and has now become the standard of care in SMA.
However, Spinraza faces stiff competition from Novartis’ (NVS - Free Report) new SMA treatment, Zolgensma, which was approved in May 2019 and is the first and only gene therapy for treating pediatric patients with SMA.
Novartis is also working to expand the label of Zolgensma, which is currently the most expensive drug available in the world.
Image: Bigstock
Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis
Biogen Inc. (BIIB - Free Report) announced that it has exercised the option to obtain worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306 from its partner Ionis Pharmaceuticals, Inc. (IONS - Free Report) . The investigational antisense oligonucleotide, BIIB115, is currently in pre-clinical development for treating spinal muscular atrophy (“SMA”).
Biogen paid $60 million to Ionis in the fourth quarter of 2021 as a part of the option exercised. The company may also make potential development, regulatory and commercial milestone payments as well as royalty payments on net sales upon potential approval. Biogen will advance the candidate to clinical studies and will now solely bear all costs and expenses related to the development, manufacturing and commercialization of BIIB115.
Shares of Biogen have decreased 2.4% in the past year compared with the industry’s decline of 22.8%.
Shares of Ionis have plunged 44.2% in the past year compared with the industry’s decrease of 19.5%.
Biogen has in-licensed Spinraza from Ionis, which is approved for treating SMA. Biogen is responsible for commercializing the drug globally. Ionis receives royalties from Biogen on Spinraza’s sales.
Biogen has expanded its collaboration with Ionis to identify new gene therapies for the treatment of SMA as well as a broad range of neurological diseases. Under these collaborations, the companies are currently developing eight medicines to treat neurodegenerative diseases like amyotrophic lateral sclerosis (“ALS”), Alzheimer’s disease and Parkinson’s disease.
Some candidates that Ionis is developing in partnership with Biogen are tofersen for SOD1-ALS (phase III), ION541 for ALS (phase II) and ION859 for Parkinson’s disease (phase II).
Spinraza has performed beyond expectations, witnessing strong patient uptake in the United States and internationally, and has now become the standard of care in SMA.
However, Spinraza faces stiff competition from Novartis’ (NVS - Free Report) new SMA treatment, Zolgensma, which was approved in May 2019 and is the first and only gene therapy for treating pediatric patients with SMA.
Novartis is also working to expand the label of Zolgensma, which is currently the most expensive drug available in the world.
Zacks Rank & Stock to Consider
Biogen and Ionis currently carry a Zacks Rank #3 (Hold). A top-ranked stock in the biotech sector is Precision BioSciences, Inc. (DTIL - Free Report) , which has a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Precision BioSciences’ loss per share estimates have narrowed 20.1% for 2022, over the past 60 days.
Precision BioSciences’ earnings have surpassed estimates in each of the trailing four quarters.